RACC SPAC to Combine With Oak Hill Bio in $175M Rare Disease Biotech Deal

In-house counsel for biotech companies, SPAC sponsors, and life sciences investors must monitor this $175M SPAC combination, which will take a rare disease antisense therapy developer public on Nasdaq by year-end 2026 and set precedent for similar rare disease biotech listings.